Andrzej Chamienia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrzej Chamienia has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
- Alicja Dębska-Ślizień
Department of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
28 shared publications B. Rutkowski
Department of Nephrology, Transplantology, and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
12 shared publications- Leszek Tylicki
Department of Nephrology, Transplantology and Internal Medicine, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
10 shared publications - Beata Bzoma
Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, Gdańsk, Poland
9 shared publications Boleslaw Rutkowski
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland
8 shared publicationsZ. Śledziński
Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdansk, Poland
7 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Impact of older donor age in kidney transplants in a biopsy-based observational study
Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Open AccessImpact of older donor age in kidney transplants in a biopsy-based observational study
Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.
- Open Access
- 23 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (1) , 117-130
Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants
- 23 August 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (1) , 117-130
Open AccessImproving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants
- Open Access
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43981
Post-transplant diabetes mellitus in kidney transplant recipients: A prospective cohort study of risk factors and clinical outcomes
Post-transplant diabetes mellitus (PTDM) is a common metabolic complication following kidney transplantation and is associated with an increased risk of graft failure, cardiovascular disease, infections, and mortality. We prospectively analyzed the risk factors and clinical consequences of PTDM in patients who underwent kidney transplantation at our center. The study included 130 transplant recipients without preexisting diabetes (79 males, 51 females; mean age: 47.6 years). PTDM was defined as the requirement for pharmacologic treatment at least 3 months after transplantation or based on the oral glucose tolerance test. The observation period ranged from 4 to 75 months. The incidence of PTDM was 21.5% (28/130). Patients who developed PTDM were older ( P = .02) and had a higher body mass index ( P = .04). Median fasting glucose and HbA1c levels prior to transplantation were significantly higher in patients who later developed PTDM. No significant differences were observed in sex, Charlson Comorbidity Index, dialysis method or duration, number of HLA mismatches, frequency of acute rejection, delayed graft function, reoperation, graft function, steroid dose, or baseline serum levels of insulin, C-peptide, lipid profile, or markers of insulin resistance. Tacrolimus was part of the immunosuppressive regimen in 89% of PTDM patients and 78% of non-PTDM patients ( P > .05). In this cohort, general risk factors for diabetes appeared to play a greater role in the development of PTDM than transplantation-specific variables. Simple pre-transplant indicators such as blood glucose and HbA1c may help identify patients at increased risk of PTDM.
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43981
Open AccessPost-transplant diabetes mellitus in kidney transplant recipients: A prospective cohort study of risk factors and clinical outcomes
Post-transplant diabetes mellitus (PTDM) is a common metabolic complication following kidney transplantation and is associated with an increased risk of graft failure, cardiovascular disease, infections, and mortality. We prospectively analyzed the risk factors and clinical consequences of PTDM in patients who underwent kidney transplantation at our center. The study included 130 transplant recipients without preexisting diabetes (79 males, 51 females; mean age: 47.6 years). PTDM was defined as the requirement for pharmacologic treatment at least 3 months after transplantation or based on the oral glucose tolerance test. The observation period ranged from 4 to 75 months. The incidence of PTDM was 21.5% (28/130). Patients who developed PTDM were older ( P = .02) and had a higher body mass index ( P = .04). Median fasting glucose and HbA1c levels prior to transplantation were significantly higher in patients who later developed PTDM. No significant differences were observed in sex, Charlson Comorbidity Index, dialysis method or duration, number of HLA mismatches, frequency of acute rejection, delayed graft function, reoperation, graft function, steroid dose, or baseline serum levels of insulin, C-peptide, lipid profile, or markers of insulin resistance. Tacrolimus was part of the immunosuppressive regimen in 89% of PTDM patients and 78% of non-PTDM patients ( P > .05). In this cohort, general risk factors for diabetes appeared to play a greater role in the development of PTDM than transplantation-specific variables. Simple pre-transplant indicators such as blood glucose and HbA1c may help identify patients at increased risk of PTDM.
- Open Access
- 15 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (10)
A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes
Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.
- 15 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (10)
Open AccessA cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes
Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.
- Open Access
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Subthreshold rejection activity in many kidney transplants currently classified as having no rejection
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Open AccessSubthreshold rejection activity in many kidney transplants currently classified as having no rejection
- Open Access
- 2 April 2024
- Published by VM Media Group sp. z o.o in Renal Disease and Transplantation Forum
- Vol. 17 (1) , 25-32
Progressive multifocal leukoencephalopathy in a kidney transplant recipient - case report and review of the literature
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the JC virus (JCV). Most cases have been reported in severely immunocompromised patients, including transplanted patients. Lesions in the white matter are the cause of neurological dysfunction. Variable neurological and psychiatric symptoms may be observed at the time of presentation. The aim of this paper is to present a case of a 58 year old female recipient of an unrelated living kidney graft, who developed PML 47 months after transplantation and a review of current literature. At the time of transplantation patient received anti-thymocyte globulin induction (ATG, Fresenius) and was then maintained on a triple immunosuppressive regimen (mycophenolate mofetil, tacrolimus and prednisolone). She presented with an abrupt onset of diplopia, vertigo and paraesthesia of the right side. MRI revealed widespread lesions in the white matter. Marked hyperproteinaemia, hypergammaglobulinemia and lymphocytosis was found in cerebrospinal fluid. Patient’s neurological status deteriorated over following two months. Suspicion of PML was raised and the dosages of mycophenolate mofetil and tacrolimus were considerably reduced. Most of the symptoms abated and 12 months later the patient complained only of occasional headaches. Repeated MRI disclosed near complete resolution of white matter lesions. Graft function temporarily worsened but then stabilized. Conclusions: 1. PML should be considered in differential diagnosis of psychiatric and neurological symptoms in transplant recipients. 2. Minimizing of immunosuppressive therapy may lead to regression of this potentially fatal disease Keywords: Progressive multifocal leukoencephalopathy renal transplantation immunosuppression
- 2 April 2024
- Published by VM Media Group sp. z o.o in Renal Disease and Transplantation Forum
- Vol. 17 (1) , 25-32
Open AccessProgressive multifocal leukoencephalopathy in a kidney transplant recipient - case report and review of the literature
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the JC virus (JCV). Most cases have been reported in severely immunocompromised patients, including transplanted patients. Lesions in the white matter are the cause of neurological dysfunction. Variable neurological and psychiatric symptoms may be observed at the time of presentation. The aim of this paper is to present a case of a 58 year old female recipient of an unrelated living kidney graft, who developed PML 47 months after transplantation and a review of current literature. At the time of transplantation patient received anti-thymocyte globulin induction (ATG, Fresenius) and was then maintained on a triple immunosuppressive regimen (mycophenolate mofetil, tacrolimus and prednisolone). She presented with an abrupt onset of diplopia, vertigo and paraesthesia of the right side. MRI revealed widespread lesions in the white matter. Marked hyperproteinaemia, hypergammaglobulinemia and lymphocytosis was found in cerebrospinal fluid. Patient’s neurological status deteriorated over following two months. Suspicion of PML was raised and the dosages of mycophenolate mofetil and tacrolimus were considerably reduced. Most of the symptoms abated and 12 months later the patient complained only of occasional headaches. Repeated MRI disclosed near complete resolution of white matter lesions. Graft function temporarily worsened but then stabilized. Conclusions: 1. PML should be considered in differential diagnosis of psychiatric and neurological symptoms in transplant recipients. 2. Minimizing of immunosuppressive therapy may lead to regression of this potentially fatal disease Keywords: Progressive multifocal leukoencephalopathy renal transplantation immunosuppression
- Open Access
- 30 June 2022
- Published by VM Media Group sp. z o.o in Renal Disease and Transplantation Forum
- Vol. 15 (2) , 63-74
Roxadustat ― new therapeutic option for treatment of anemia in patients with chronic kidney disease
Chronic kidney disease (CKD) is an increasingly common public health issue. It is estimated that it affects 8–16% of the global population. Anemia is a very common complication of chronic kidney disease, and its occurrence is associated with a reduced quality of life, increased morbidity, and mortality. The main causes of CKD anemia include erythropoietin (EPO) deficiency and iron deficiency (absolute and functional). In addition, the bone marrow response to EPO is reduced in patients with chronic inflammation, which is often present in patients with advanced stages of CKD and dialyzed patients. According to the current guidelines, the treatment of anemia in CKD involves recombinant erythropoiesis-stimulating agents (ESAs) along with iron supplementation. In some patients, intensive correction of anemia requiring high doses of ESA and intravenous iron may increase the risk of adverse events. The correction also requires injections, outpatient visits, and hospital stays, which is especially troublesome for pre-dialysis patients. The discovery of hypoxia-inducible factors (HIFs) responsible for stimulating cells to EPO synthesis and increased activity of oxygen-dependent genes enabled the development of new drugs, so-called HIF-PHI inhibitors (hypoxia-inducible factor-prolyl hydroxylase inhibitors, prolyl hydroxylase inhibitors). Those compounds reversibly inhibit the activityof the enzyme responsible for inactivating the HIF and thus increase endogenous EPO synthesis and affect iron metabolism. This discovery opened new options for the treatment of anemia in CKD patients. Phase 2 and 3 clinical trials are conducted with several drugs: daprodustat (GSK-1278863), roxadustat (FG-4592), and wadadustat (AKB-6548). To date, only roxadustat has been approved for treatment of CKD-related anemia. Roxadustat (FG-4592) is a novel orally active, potent, and reversible inhibitor of prolyl hydroxylase (PHI), causing functional activation of target genes that encode proteins such as EPO, EPO receptor, heme biosynthesis enzymes, and proteins that enhance iron absorption and transport and thus promote formation and maturation of red blood cells (RBCs). This study aims to summarize the available results of studies on the use of roxadustat in Keywords: chronic kidney disease anemia erythropoiesis stimulating agents prolyl hydroxylase inhibitors
- 30 June 2022
- Published by VM Media Group sp. z o.o in Renal Disease and Transplantation Forum
- Vol. 15 (2) , 63-74
Open AccessRoxadustat ― new therapeutic option for treatment of anemia in patients with chronic kidney disease
Chronic kidney disease (CKD) is an increasingly common public health issue. It is estimated that it affects 8–16% of the global population. Anemia is a very common complication of chronic kidney disease, and its occurrence is associated with a reduced quality of life, increased morbidity, and mortality. The main causes of CKD anemia include erythropoietin (EPO) deficiency and iron deficiency (absolute and functional). In addition, the bone marrow response to EPO is reduced in patients with chronic inflammation, which is often present in patients with advanced stages of CKD and dialyzed patients. According to the current guidelines, the treatment of anemia in CKD involves recombinant erythropoiesis-stimulating agents (ESAs) along with iron supplementation. In some patients, intensive correction of anemia requiring high doses of ESA and intravenous iron may increase the risk of adverse events. The correction also requires injections, outpatient visits, and hospital stays, which is especially troublesome for pre-dialysis patients. The discovery of hypoxia-inducible factors (HIFs) responsible for stimulating cells to EPO synthesis and increased activity of oxygen-dependent genes enabled the development of new drugs, so-called HIF-PHI inhibitors (hypoxia-inducible factor-prolyl hydroxylase inhibitors, prolyl hydroxylase inhibitors). Those compounds reversibly inhibit the activityof the enzyme responsible for inactivating the HIF and thus increase endogenous EPO synthesis and affect iron metabolism. This discovery opened new options for the treatment of anemia in CKD patients. Phase 2 and 3 clinical trials are conducted with several drugs: daprodustat (GSK-1278863), roxadustat (FG-4592), and wadadustat (AKB-6548). To date, only roxadustat has been approved for treatment of CKD-related anemia. Roxadustat (FG-4592) is a novel orally active, potent, and reversible inhibitor of prolyl hydroxylase (PHI), causing functional activation of target genes that encode proteins such as EPO, EPO receptor, heme biosynthesis enzymes, and proteins that enhance iron absorption and transport and thus promote formation and maturation of red blood cells (RBCs). This study aims to summarize the available results of studies on the use of roxadustat in Keywords: chronic kidney disease anemia erythropoiesis stimulating agents prolyl hydroxylase inhibitors
- Open Access
Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project
Background: The efficacy of SARS-CoV-2 vaccination among kidney transplant recipients (KTR) is low. The main goal of this study was to analyze factors that may influence the humoral response to vaccination. Methods: We analyzed the titer magnitude of IgG antibodies directed against spike (S)-SARS-CoV-2 antigen after the second dose of the mRNA vaccine in 142 infection naïve KTR (83 men, i.e., 58.4%) with a median age (IQR) of 54 (41–63), and 36 respective controls without chronic kidney disease. mRNA-1273 or BNT162b2 were applied in 26% and 74% of KTR, respectively. Results: S-specific immune response (seroconversion) was seen in 73 (51.41%) of KTR, and in all controls 36 (100%). Independent predictors of no response were elder age, shorter transplantation vintage, and a more than two-drug immunosuppressive protocol. In subgroup analyses, the seroconversion rate was highest among KTR without MMF/MPS treatment (70%), treated with no more than two immunosuppressants (69.2%), treated without corticosteroid (66.7%), younger patients aged <54 years (63.2%), and those vaccinated with the mRNA-1273 vaccine (62.16%). The independent predictors of higher S-antibody titer among responders were younger age, treatment with no more than two immunosuppressants, and the mRNA-1273 vaccination. Conclusions: Our study confirmed a low rate of seroconversion after vaccination with the mRNA vaccine in KTR. The major modifiable determinants of humoral response were the composition of the immunosuppressive protocol, as well as the type of vaccine. The latter could be taken into consideration when initial vaccination as well as booster vaccination is considered in KTR.
Open AccessPredictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project
Background: The efficacy of SARS-CoV-2 vaccination among kidney transplant recipients (KTR) is low. The main goal of this study was to analyze factors that may influence the humoral response to vaccination. Methods: We analyzed the titer magnitude of IgG antibodies directed against spike (S)-SARS-CoV-2 antigen after the second dose of the mRNA vaccine in 142 infection naïve KTR (83 men, i.e., 58.4%) with a median age (IQR) of 54 (41–63), and 36 respective controls without chronic kidney disease. mRNA-1273 or BNT162b2 were applied in 26% and 74% of KTR, respectively. Results: S-specific immune response (seroconversion) was seen in 73 (51.41%) of KTR, and in all controls 36 (100%). Independent predictors of no response were elder age, shorter transplantation vintage, and a more than two-drug immunosuppressive protocol. In subgroup analyses, the seroconversion rate was highest among KTR without MMF/MPS treatment (70%), treated with no more than two immunosuppressants (69.2%), treated without corticosteroid (66.7%), younger patients aged <54 years (63.2%), and those vaccinated with the mRNA-1273 vaccine (62.16%). The independent predictors of higher S-antibody titer among responders were younger age, treatment with no more than two immunosuppressants, and the mRNA-1273 vaccination. Conclusions: Our study confirmed a low rate of seroconversion after vaccination with the mRNA vaccine in KTR. The major modifiable determinants of humoral response were the composition of the immunosuppressive protocol, as well as the type of vaccine. The latter could be taken into consideration when initial vaccination as well as booster vaccination is considered in KTR.
- Open Access
- 20 December 2018
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 25 (4) , 616-624
Stress factors vs. job satisfaction among nursing staff in the Pomeranian Province (Poland) and the Vilnius Region (Lithuania)
Introduction: In the opinion of many researchers, nursing staff are exposed to an exceptionally high level of occupational stress. The problem of stress in the working environment of the nursing staff becomes more and more important in the context of increasing staff shortages and insufficient...
- 20 December 2018
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 25 (4) , 616-624
Open AccessStress factors vs. job satisfaction among nursing staff in the Pomeranian Province (Poland) and the Vilnius Region (Lithuania)
Introduction: In the opinion of many researchers, nursing staff are exposed to an exceptionally high level of occupational stress. The problem of stress in the working environment of the nursing staff becomes more and more important in the context of increasing staff shortages and insufficient...
- 1 July 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1646-1653
Paired Analysis of Outcomes After Kidney Transplantation in Peritoneal and Hemodialysis Patients
- 1 July 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (6) , 1646-1653
Paired Analysis of Outcomes After Kidney Transplantation in Peritoneal and Hemodialysis Patients